The use of reagent “NCC onco panel” developed based on the characteristics of Japanese seems to be a feature of profiling. For details, please see the following URL: https: //www.ncc.go.jp/jp/information/pr_release/2018/0403_2/index.html
National Cancer Research Center Central Hospital
Genetic testing to examine cancer-related genes exhaustively Performed in advanced medical treatment
TOP-GEAR project aimed for insurance application of inspection system constructed by TOP-GEAR project
April 3, 2018
National Cancer Research Center
National Hospital Research Center for National Cancer Research (President: Norihisa Nakamura) Central Hospital (Hospital Director: Toshiro Nishida, Location: Chuo Ward, Tokyo) gathers genes related to cancer of a patient in one comprehensive examination We will conduct genetic testing on advanced medicine B on 9th April, which will be useful for selection of anticancer drugs.
(Explanation page for advanced medical care for patients https://www.ncc.go.jp/jp/ncch/information/20180403/index.html )
This genetic test was conducted by using the reagent “NCC Onco Panel” developed by the National Cancer Research Center based on the characteristics of the Japanese, to analyze 114 gene mutations associated with cancer and 12 fusion gene mutations once You can check it by inspection. Development of programs to be used for analysis, such as examination at “NCC Onco Panel”, expert panel implementation method to decide policy based on analysis result, hospital system, etc. are clinical research “TOP- GEAR (Top – Gear) Project “(started in July 2013 UMIN000011141). We are currently constructing it as a series of inspection systems and aiming to apply for pharmaceuticals approval and insurance application with Sysmex Corporation as pharmaceuticals and medical devices for in vitro diagnosis.
Advanced medical care B is to evaluate efficacy and safety in clinical research in order to examine whether it is subject to insurance application. This Advanced Medicine will be implemented as “Multiplex Genetic Panel Inspection Study for Individualized Medicine”.
The subject is a solid cancer patient who has no standard treatment of 16 years old or older or has completed (including expectation) even with standard treatment, or a patient with unknown primary cancer, National Cancer Research Center Central Hospital In addition to cooperating with cancer cancer center core hospitals and cancer genome medical cooperative hospitals in the future, we participate in up to 350 patients from 205 cases and verify the usefulness of NCC onco-panel examination I will. Subsequently, based on the results of genetic tests, we selected drugs including not only approved drugs but also unapproved drugs and drugs that are not approved, including drug trials and doctor-initiated trials, and also confirm the effectiveness of insurance application I will aim.
Go Back to Innovation
Copyright © GloriaLTH All Rights Reserved
